Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Anthony David Elias

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone720/848-0347

    Collapse Research 
    Collapse research activities and funding
    UG1CA233324     (ELIAS, ANTHONY D)Mar 29, 2019 - Feb 28, 2025
    NIH
    NCI National Clinical Trials Network - Lead Academic Participant Sites
    Role: Principal Investigator
    U10CA180834     (ELIAS, ANTHONY D)Apr 14, 2014 - Feb 28, 2019
    NIH
    University of Colorado NTCN Lead Academic Participating Site (LAPS)
    Role: Principal Investigator
    R21CA081324     (ELIAS, ANTHONY D)Apr 5, 1999 - Mar 31, 2003
    NIH
    MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
    Role: Principal Investigator
    U10CA042777     (ELIAS, ANTHONY D)Jan 1, 1988 - Dec 31, 2015
    NIH
    University of Colorado Southwest Oncology Group
    Role: Principal Investigator
    P01CA038493     (ELIAS, ANTHONY D)Jul 1, 1985 - Nov 30, 1999
    NIH
    SOLID TUMOR AUTOLOGOUS MARROW PROGRAM
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740. PMID: 38109213.
      View in: PubMed
    2. Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2349646. PMID: 38153734.
      View in: PubMed
    3. Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 03; 15(15). PMID: 37568766.
      View in: PubMed
    4. Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 08 01; 83(15):2543-2556. PMID: 37205634.
      View in: PubMed
    5. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. NCCN Guidelines? Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 06; 21(6):594-608. PMID: 37308117.
      View in: PubMed
    6. Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20; 9(1):41. PMID: 37210417.
      View in: PubMed
    7. Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 05; 185:69-82. PMID: 36965330.
      View in: PubMed
    8. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840.
      View in: PubMed
    9. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128. PMID: 36456573.
      View in: PubMed
    10. Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163. PMID: 36215947.
      View in: PubMed
    11. Subbiah V, Bra?a I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770. PMID: 35486638.
      View in: PubMed
    12. Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 09 20; 40(27):3205-3221. PMID: 35759724.
      View in: PubMed
    13. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722. PMID: 35714673.
      View in: PubMed
    14. Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10; 8(1):62. PMID: 35538119.
      View in: PubMed
    15. Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823. PMID: 35513244.
      View in: PubMed
    16. Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr?schel S, Hatcher H, Duffaud F, Herr?ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G?tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490. PMID: 35394800.
      View in: PubMed
    17. Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 03; 61(3):359-371. PMID: 34856027.
      View in: PubMed
    18. Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428. PMID: 34741023.
      View in: PubMed
    19. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663. PMID: 34529000.
      View in: PubMed
    20. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. PMID: 34611148.
      View in: PubMed
    21. Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 04 20; 40(12):1291-1300. PMID: 34260265.
      View in: PubMed
    22. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5. PMID: 34143979.
      View in: PubMed
    23. Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol. 2021 08 20; 39(24):2720-2731. PMID: 34003702.
      View in: PubMed
    24. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. NCCN Guidelines? Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493. PMID: 34794122.
      View in: PubMed
    25. Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Mol Cancer Ther. 2021 06; 20(6):1062-1071. PMID: 33722849.
      View in: PubMed
    26. Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, Armeson KE, Schuetze SM, Meyer CF, Reuben DY, Elias AD, Read WL, Chawla SP, Kraft AS. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904. PMID: 33231866.
      View in: PubMed
    27. Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer. Cancer Res. 2021 02 01; 81(3):732-746. PMID: 33184106.
      View in: PubMed
    28. Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808. PMID: 33063469.
      View in: PubMed
    29. Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. PMID: 32701140.
      View in: PubMed
    30. Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139. PMID: 32822091.
      View in: PubMed
    31. Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 07 01; 112(7):698-707. PMID: 31693129.
      View in: PubMed
    32. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. PMID: 32053137.
      View in: PubMed
    33. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478. PMID: 32259783.
      View in: PubMed
    34. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. PMID: 32031889.
      View in: PubMed
    35. Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126. PMID: 30787125.
      View in: PubMed
    36. Hoffner B, Elias AD, Villalobos VM. Targeted Therapies in the Treatment of Sarcomas. Target Oncol. 2018 10; 13(5):557-565. PMID: 30143942.
      View in: PubMed
    37. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019 Jan; 173(1):37-48. PMID: 30267249.
      View in: PubMed
    38. Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 09 01; 29(9):1995-2002. PMID: 30084934.
      View in: PubMed
    39. Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 08 02; 20(1):82. PMID: 30071865.
      View in: PubMed
    40. Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14). PMID: 30046001.
      View in: PubMed
    41. Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018 Aug; 171(1):11-20. PMID: 29725889.
      View in: PubMed
    42. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2018 05; 16(5S):605-610. PMID: 29784737.
      View in: PubMed
    43. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320. PMID: 29523670.
      View in: PubMed
    44. Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7. PMID: 29352368.
      View in: PubMed
    45. Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Horm Cancer. 2018 04; 9(2):82-94. PMID: 29340907.
      View in: PubMed
    46. Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 11; 23(6):627-629. PMID: 29112794.
      View in: PubMed
    47. Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces. 2018 Jan 01; 161:200-209. PMID: 29080504.
      View in: PubMed
    48. Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar; 25(3):768-775. PMID: 28887726.
      View in: PubMed
    49. Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 07 01; 77(13):3455-3466. PMID: 28512248.
      View in: PubMed
    50. Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Mol Cancer Ther. 2017 07; 16(7):1389-1400. PMID: 28468774.
      View in: PubMed
    51. Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503. PMID: 28404760.
      View in: PubMed
    52. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 04; 15(4):433-451. PMID: 28404755.
      View in: PubMed
    53. Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA, Traina TA. A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4046-4054. PMID: 28280092.
      View in: PubMed
    54. Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70. PMID: 27987198.
      View in: PubMed
    55. Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721. PMID: 27702820.
      View in: PubMed
    56. Villalobos VM, Hoffner B, Elias AD. We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas. Cancer. 2017 01 01; 123(1):20-24. PMID: 27696384.
      View in: PubMed
    57. Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Sch?ffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905. PMID: 27621408.
      View in: PubMed
    58. D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 11; 14(11):1054-1067. PMID: 27565181.
      View in: PubMed
    59. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
      View in: PubMed
    60. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
      View in: PubMed
    61. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97. PMID: 27291997.
      View in: PubMed
    62. Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol. 2016 10; 56:40-51. PMID: 27260947.
      View in: PubMed
    63. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016 Jul; 8(4):305-8. PMID: 27482289.
      View in: PubMed
    64. Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 06 10; 34(17):1995-2002. PMID: 27001563.
      View in: PubMed
    65. Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016 Mar 15; 18(1):34. PMID: 26979312.
      View in: PubMed
    66. Sedjo RL, Flatt SW, Byers T, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Wyatt H, Rock CL. Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Support Care Cancer. 2016 08; 24(8):3285-93. PMID: 26945570.
      View in: PubMed
    67. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54. PMID: 26957618.
      View in: PubMed
    68. Elias AD, Wang WS, Hardesty L. A 55-Year-Old Woman With New Triple-Negative Breast Mass, Less Than 2 cm on Both Mammogram and Ultrasound. Oncology (Williston Park). 2016 Mar; 30(3):258-62. PMID: 26984221.
      View in: PubMed
    69. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85. PMID: 26656517.
      View in: PubMed
    70. Demark-Wahnefried W, Colditz GA, Rock CL, Sedjo RL, Liu J, Wolin KY, Krontiras H, Byers T, Pakiz B, Parker BA, Naughton M, Elias A, Ganz PA. Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Res Treat. 2015 Nov; 154(2):329-37. PMID: 26518022.
      View in: PubMed
    71. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93. PMID: 26371143.
      View in: PubMed
    72. Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep; 29(9):669-70, 678-9. PMID: 26384804.
      View in: PubMed
    73. Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. J Clin Oncol. 2015 Oct 01; 33(28):3169-76. PMID: 26282657.
      View in: PubMed
    74. Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015 Dec; 6(5-6):206-13. PMID: 26201402.
      View in: PubMed
    75. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75. PMID: 25870381.
      View in: PubMed
    76. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686.
      View in: PubMed
    77. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar; 14(3):769-78. PMID: 25713333.
      View in: PubMed
    78. Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF. Management of young breast cancer patients with de novo genetic mutations. Oncology (Williston Park). 2014 Oct; 28(10):895-6. PMID: 25323616.
      View in: PubMed
    79. Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul; 16(7):1006-9. PMID: 24497407.
      View in: PubMed
    80. Lopez JP, Gajdos C, Elias A. Trabectedin: novel insights in the treatment of advanced sarcoma. Curr Oncol Rep. 2014 Jun; 16(6):387. PMID: 24756367.
      View in: PubMed
    81. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90. PMID: 24717572.
      View in: PubMed
    82. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41. PMID: 24670685.
      View in: PubMed
    83. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, G?mez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1):R7. PMID: 24451109.
      View in: PubMed
    84. Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the aorta: a systematic review and pooled analysis of published reports. Ann Vasc Surg. 2014 Feb; 28(2):515-25. PMID: 24485779.
      View in: PubMed
    85. Curigliano G, Pivot X, Cort?s J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013 Oct; 22(5):650-6. PMID: 23958375.
      View in: PubMed
    86. Sch?ffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013 Oct; 49(15):3219-28. PMID: 23835252.
      View in: PubMed
    87. Elias AD, Sams S. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR. Oncology (Williston Park). 2013 Jun; 27(6):526-7, 566. PMID: 23909065.
      View in: PubMed
    88. Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H. Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial. Contemp Clin Trials. 2013 Mar; 34(2):282-95. PMID: 23266440.
      View in: PubMed
    89. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      View in: PubMed
    90. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15; 1(1):16. PMID: 23369448.
      View in: PubMed
    91. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32. PMID: 22821401.
      View in: PubMed
    92. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer. 2012 Sep 01; 118(17):4098-104. PMID: 22281842.
      View in: PubMed
    93. Elias AD. Management of Small T1a/b N0 Breast Cancers. Am Soc Clin Oncol Educ Book. 2012; 10-9. PMID: 24451702.
      View in: PubMed
    94. Borges VF, Elias AD. The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. J Clin Oncol. 2011 Aug 20; 29(24):3205-6. PMID: 21768457.
      View in: PubMed
    95. Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein CE, Elias A, Finlayson C, Borges VF. Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park). 2011 Apr 15; 25(4):351-6. PMID: 21618957.
      View in: PubMed
    96. Gajdos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol. 2011 Mar 16; 5:35-43. PMID: 21499557.
      View in: PubMed
    97. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010 Dec; 33(6):637-45. PMID: 20023571.
      View in: PubMed
    98. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010 Dec; 1(6):306-19. PMID: 21761362.
      View in: PubMed
    99. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55. PMID: 20665103.
      View in: PubMed
    100. Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Clin Breast Cancer. 2010 Apr; 10(2):148-53. PMID: 20299319.
      View in: PubMed
    101. Weitzel LR, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Queensland KM, Singh M, Wischmeyer PE, Duncan MW, Elias A. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat. 2010 Nov; 124(2):297-305. PMID: 20087651.
      View in: PubMed
    102. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21. PMID: 19933919.
      View in: PubMed
    103. Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91. PMID: 19777765.
      View in: PubMed
    104. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blach?re NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40. PMID: 19451436.
      View in: PubMed
    105. Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer. Oncology (Williston Park). 2008 Oct; 22(11):1270-6. PMID: 18980024.
      View in: PubMed
    106. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. PMID: 18347007.
      View in: PubMed
    107. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501. PMID: 18338247.
      View in: PubMed
    108. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88. PMID: 18327671.
      View in: PubMed
    109. Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score. Oncology (Williston Park). 2007 Sep; 21(10):1212-7. PMID: 17926799.
      View in: PubMed
    110. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007 May 01; 25(13):1677-82. PMID: 17404368.
      View in: PubMed
    111. Menter A, Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Finlayson C, Elias A. A woman with primary breast cancer and a solitary sternal metastasis. Oncology (Williston Park). 2006 Aug; 20(9):1068-71, 1075, 1079-80. PMID: 16986350.
      View in: PubMed
    112. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006 May 15; 12(10):3124-9. PMID: 16707611.
      View in: PubMed
    113. Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology (Williston Park). 2005 Mar; 19(3):278, 283-4, 287 passim. PMID: 15828548.
      View in: PubMed
    114. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 2004; 6(2):93-101. PMID: 14979914.
      View in: PubMed
    115. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003 Feb; 77(3):245-52. PMID: 12602924.
      View in: PubMed
    116. Elias AD, Kumar P, Herndon J, Skarin AT, Sugarbaker DJ, Green MR. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clin Lung Cancer. 2002 Sep; 4(2):95-103. PMID: 14653865.
      View in: PubMed
    117. Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant. 2002; 8(6):326-33. PMID: 12108918.
      View in: PubMed
    118. Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205. PMID: 12017145.
      View in: PubMed
    119. Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9. PMID: 11561781.
      View in: PubMed
    120. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78. PMID: 11277174.
      View in: PubMed
    121. Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma. 2001 Feb; 40(5-6):499-509. PMID: 11426523.
      View in: PubMed
    122. Elias AD. High dose chemotherapy with stem cell rescue for breast cancer: current status and future directions. Breast Dis. 2001; 14:51-68. PMID: 15687636.
      View in: PubMed
    123. Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76. PMID: 10918427.
      View in: PubMed
    124. Kraeft SK, Sutherland R, Gravelin L, Hu GH, Ferland LH, Richardson P, Elias A, Chen LB. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res. 2000 Feb; 6(2):434-42. PMID: 10690521.
      View in: PubMed
    125. Frei E, Ara G, Teicher B, Bunnell C, Richardson P, Wheeler C, Tew K, Elias A. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46. PMID: 10663642.
      View in: PubMed
    126. Anderson WF, Reeves JE, Elias A, Berkel H. Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer. 2000 Jan 01; 88(1):95-107. PMID: 10618611.
      View in: PubMed
    127. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95. PMID: 11063377.
      View in: PubMed
    128. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest. 1999 Dec; 116(6 Suppl):531S-538S. PMID: 10619526.
      View in: PubMed
    129. Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45. PMID: 10556951.
      View in: PubMed
    130. Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41. PMID: 10537336.
      View in: PubMed
    131. Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol. 1999 Apr; 17(4):1175. PMID: 10561176.
      View in: PubMed
    132. Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998 Sep; 4(9):2027-37. PMID: 9748116.
      View in: PubMed
    133. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. PMID: 9680339.
      View in: PubMed
    134. Avigan D, Richardson P, Elias A, Demetri G, Shapiro M, Schnipper L, Wheeler C. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14. PMID: 9690531.
      View in: PubMed
    135. Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clin Cancer Res. 1998 Jun; 4(6):1443-9. PMID: 9626461.
      View in: PubMed
    136. Elias AD. High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol. 1998 Apr; 25(2 Suppl 4):19-23; discussion 45-8. PMID: 9578058.
      View in: PubMed
    137. Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998 Mar; 16(3):1000-7. PMID: 9508183.
      View in: PubMed
    138. Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15; 91(2):717-23. PMID: 9427731.
      View in: PubMed
    139. Elias A. Dose-intensive therapy in small cell lung cancer. Chest. 1998 Jan; 113(1 Suppl):101S-106S. PMID: 9438698.
      View in: PubMed
    140. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997 Oct; 112(4 Suppl):251S-258S. PMID: 9337299.
      View in: PubMed
    141. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PMID: 9331127.
      View in: PubMed
    142. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106. PMID: 9267670.
      View in: PubMed
    143. Elias AD. Future directions in lung cancer research and therapeutics. Hematol Oncol Clin North Am. 1997 Jun; 11(3):519-27. PMID: 9209908.
      View in: PubMed
    144. Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E, Sugarbaker DJ. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997 May; 17(1):147-61. PMID: 9194034.
      View in: PubMed
    145. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997 Feb; 15(2):674-83. PMID: 9053493.
      View in: PubMed
    146. Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34. PMID: 9053498.
      View in: PubMed
    147. Elias A. Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol. 1997; 40 Suppl:S64-9. PMID: 9272137.
      View in: PubMed
    148. Chen L, Pulsipher M, Chen D, Sieff C, Elias A, Fine HA, Kufe DW. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996 Dec 01; 98(11):2539-48. PMID: 8958216.
      View in: PubMed
    149. Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):179-94. PMID: 8953602.
      View in: PubMed
    150. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92. PMID: 8918496.
      View in: PubMed
    151. Webb IJ, Coral FS, Andersen JW, Elias AD, Finberg RW, Nadler LM, Ritz J, Anderson KC. Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 1996 Sep; 36(9):782-8. PMID: 8823450.
      View in: PubMed
    152. Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 1996 Jun 01; 77(11):2393-9. PMID: 8635112.
      View in: PubMed
    153. Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, Demetri GD, Anderson KC. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. Transfusion. 1996 Feb; 36(2):160-7. PMID: 8614968.
      View in: PubMed
    154. Benjamin RJ, Linsley L, Axelrod JD, Churchill WH, Sieff C, Shulman LN, Elias A, Ayash L, Malachowski ME, Uhl L, et al. The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high-dose chemotherapy support. Transfusion. 1995 Oct; 35(10):837-44. PMID: 7570914.
      View in: PubMed
    155. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug; 9(4):765-85. PMID: 7490240.
      View in: PubMed
    156. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9. PMID: 7636547.
      View in: PubMed
    157. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, et al. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):70-4. PMID: 7544029.
      View in: PubMed
    158. Elias AD. Dose-intensive therapy for small cell lung cancer. Chest. 1995 Jun; 107(6 Suppl):261S-266S. PMID: 7781403.
      View in: PubMed
    159. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 1995 Mar; 15(3):373-9. PMID: 7599561.
      View in: PubMed
    160. Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Antman K, Rosowsky A, Frel E, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36(4):345-51. PMID: 7628055.
      View in: PubMed
    161. Wright JE, Tretyakov O, Ayash LJ, Elias A, Rosowsky A, Frei E. Analysis of 4-hydroxycyclophosphamide in human blood. Anal Biochem. 1995 Jan 01; 224(1):154-8. PMID: 7710063.
      View in: PubMed
    162. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol. 1994 Oct; 21(5 Suppl 12):83-5. PMID: 7992072.
      View in: PubMed
    163. Elias AD. Salvage therapy for soft tissue sarcomas. Semin Oncol. 1994 Aug; 21(4 Suppl 7):76-81. PMID: 8091245.
      View in: PubMed
    164. Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, Lynch T, Levitt D, Resta D, Demetri G, et al. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol. 1994 Aug; 87(4):678-86. PMID: 7986706.
      View in: PubMed
    165. Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol. 1994 May; 87(1):153-61. PMID: 7947240.
      View in: PubMed
    166. Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer. 1994 Feb 15; 73(4):1171-6. PMID: 8313319.
      View in: PubMed
    167. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Feb; 12(2):347-52. PMID: 8113842.
      View in: PubMed
    168. Elias AD, Skarin AT, Gonin R, Oliynyk P, Stomper PC, O'Hara C, Socinski MA, Sheldon T, Maggs P, Frei E. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol. 1994 Feb; 17(1):26-36. PMID: 8311004.
      View in: PubMed
    169. Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr. 1994; (16):91-4. PMID: 7528031.
      View in: PubMed
    170. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol. 1994 Jan; 12(1):37-44. PMID: 7505807.
      View in: PubMed
    171. Kirn DH, Lynch TJ, Mentzer SJ, Lee TH, Strauss GM, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. J Thorac Cardiovasc Surg. 1993 Oct; 106(4):696-702. PMID: 8412265.
      View in: PubMed
    172. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85. PMID: 8315425.
      View in: PubMed
    173. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. PMID: 8099120.
      View in: PubMed
    174. Lynch TJ, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E. Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. Cancer. 1993 May 15; 71(10):2953-7. PMID: 8387871.
      View in: PubMed
    175. Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993 Apr 07; 85(7):559-66. PMID: 8384264.
      View in: PubMed
    176. Elias AD, Ayash L, Skarin AT, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper L, Frei E, Antman KH. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):433S-435S. PMID: 8096454.
      View in: PubMed
    177. Elias AD. Chemotherapy for soft-tissue sarcomas. Clin Orthop Relat Res. 1993 Apr; (289):94-105. PMID: 8472436.
      View in: PubMed
    178. Elias A. Chemotherapy and radiotherapy for regionally advanced non-small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):362S-366S. PMID: 8384971.
      View in: PubMed
    179. Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother. 1993; 2(4):507-11. PMID: 7916250.
      View in: PubMed
    180. Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E, Antman K. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother. 1993; 2(3):377-82. PMID: 7522891.
      View in: PubMed
    181. Lynch TJ, Clark JR, Kalish LA, Fallon BG, Elias AD, Skarin A, Frei E. Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer. Cancer. 1992 Oct 01; 70(7):1880-5. PMID: 1326396.
      View in: PubMed
    182. Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JA, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med. 1992 Sep; 33(9):1594-9. PMID: 1517831.
      View in: PubMed
    183. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992 Jul; 10(1):57-63. PMID: 1515880.
      View in: PubMed
    184. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992 Jun; 10(6):995-1000. PMID: 1588381.
      View in: PubMed
    185. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, Tepler I, Mazanet R, Lynch C, Pap S, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992 Jun 01; 79(11):3036-44. PMID: 1350229.
      View in: PubMed
    186. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol. 1992 May; 10(5):829-38. PMID: 1314892.
      View in: PubMed
    187. Elias AD. The clinical management of soft tissue sarcomas. Semin Oncol. 1992 Feb; 19(1 Suppl 1):19-25. PMID: 1411616.
      View in: PubMed
    188. Elias AD. Future directions in the management of soft tissue sarcomas. Hematol Oncol. 1992 Jan-Feb; 10(1):53-60. PMID: 1563704.
      View in: PubMed
    189. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan; 10(1):102-10. PMID: 1727912.
      View in: PubMed
    190. Elias AD, Mazanet R, Wheeler C, Anderson K, Ayash L, Schwartz G, Tepler I, Pap S, Pelaez J, Hunt M, et al. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S25-9. PMID: 1687204.
      View in: PubMed
    191. Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1991 Aug; 3(4):671-6. PMID: 1932226.
      View in: PubMed
    192. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb; 9(2):320-7. PMID: 1846407.
      View in: PubMed
    193. Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol. 1991; 29(1):61-5. PMID: 1742850.
      View in: PubMed
    194. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E, et al. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. J Cancer Res Clin Oncol. 1991; 117 Suppl 4:S208-13. PMID: 1795009.
      View in: PubMed
    195. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706. PMID: 2213105.
      View in: PubMed
    196. Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul; 8(7):1239-45. PMID: 2162912.
      View in: PubMed
    197. Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1990 Jun; 2(3):474-80. PMID: 2092763.
      View in: PubMed
    198. Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 1990 May 15; 75(10):2035-41. PMID: 2337672.
      View in: PubMed
    199. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73. PMID: 2110386.
      View in: PubMed
    200. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990 Apr; 17(2 Suppl 4):41-9. PMID: 2110385.
      View in: PubMed
    201. Tondini C, Pap SA, Hayes DF, Elias AD, Kufe DW. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res. 1990 Feb 15; 50(4):1170-5. PMID: 2404589.
      View in: PubMed
    202. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol. 1990 Feb; 17(1 Suppl 2):7-15. PMID: 2106162.
      View in: PubMed
    203. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol. 1990 Feb; 17(1 Suppl 3):33-8. PMID: 2106166.
      View in: PubMed
    204. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan; 8(1):170-8. PMID: 2104923.
      View in: PubMed
    205. Elias AD, Pap SA, Bernal SD. Purging of small cell lung cancer-contaminated bone marrow by monoclonal antibodies and magnetic beads. Prog Clin Biol Res. 1990; 333:263-75. PMID: 2155434.
      View in: PubMed
    206. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep; 7(9):1208-16. PMID: 2504890.
      View in: PubMed
    207. Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol. 1989 Aug; 16(4):305-11. PMID: 2667145.
      View in: PubMed
    208. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May; 7(5):651-61. PMID: 2651580.
      View in: PubMed
    209. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31. PMID: 2491883.
      View in: PubMed
    210. Bernal SD, Elias AD. Early lung cancer detection: monoclonal antibody staining of exfoliated cells in sputum. J Clin Oncol. 1988 Nov; 6(11):1676-8. PMID: 2460593.
      View in: PubMed
    211. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst. 1988 Oct 05; 80(15):1221-6. PMID: 3138431.
      View in: PubMed
    212. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8. PMID: 3045544.
      View in: PubMed
    213. Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol. 1988 Jun; 124(6):878-84. PMID: 3288124.
      View in: PubMed
    214. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009.
      View in: PubMed
    215. Elias AD, Cohen BF, Bernal SD. Keratin subtypes of small cell lung cancer. Cancer Res. 1988 May 15; 48(10):2724-9. PMID: 2452011.
      View in: PubMed
    216. Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988; 4(1):53-8. PMID: 3281212.
      View in: PubMed
    217. Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65. PMID: 3281213.
      View in: PubMed
    218. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep. 1987 Nov; 71(11):1043-7. PMID: 3119200.
      View in: PubMed
    219. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25. PMID: 3542208.
      View in: PubMed
    220. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7. PMID: 3534155.
      View in: PubMed
    221. Elias AD, Antman KH. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. Cancer Treat Rep. 1986 Jul; 70(7):827-33. PMID: 3087617.
      View in: PubMed
    222. Elias AD, Elias ER. Matching of couples in the NRMP. N Engl J Med. 1980 Jun 19; 302(25):1425-6. PMID: 7374708.
      View in: PubMed
    Elias's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (606) concept(s)
    _
    Co-Authors Expand Description
    See all (59) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)